|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0086661,
umls-concept:C0162638,
umls-concept:C0174680,
umls-concept:C0205177,
umls-concept:C0752313,
umls-concept:C0935989,
umls-concept:C1280500,
umls-concept:C1512167,
umls-concept:C1527027,
umls-concept:C2349975
|
|
pubmed:issue |
5A
|
|
pubmed:dateCreated |
2004-11-2
|
|
pubmed:abstractText |
Imatinib mesylate (ST1571) is the first-line drugfor chronic myeloid leukemia (CML), but development of resistance to this drug is a clinical problem. To explore the effective use of ST1571, we studied the combination treatment with histone deacetylase inhibitor (depsipeptide, FK228).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Depsipeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Histones,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxamic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-myc,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib,
http://linkedlifedata.com/resource/pubmed/chemical/romidepsin,
http://linkedlifedata.com/resource/pubmed/chemical/trichostatin A
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2705-12
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15517875-Acetylation,
pubmed-meshheading:15517875-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15517875-Apoptosis,
pubmed-meshheading:15517875-Cyclin D1,
pubmed-meshheading:15517875-Depsipeptides,
pubmed-meshheading:15517875-Dose-Response Relationship, Drug,
pubmed-meshheading:15517875-Drug Synergism,
pubmed-meshheading:15517875-Fusion Proteins, bcr-abl,
pubmed-meshheading:15517875-Histones,
pubmed-meshheading:15517875-Humans,
pubmed-meshheading:15517875-Hydroxamic Acids,
pubmed-meshheading:15517875-Immunoblotting,
pubmed-meshheading:15517875-K562 Cells,
pubmed-meshheading:15517875-MAP Kinase Kinase Kinases,
pubmed-meshheading:15517875-MAP Kinase Signaling System,
pubmed-meshheading:15517875-Piperazines,
pubmed-meshheading:15517875-Proto-Oncogene Proteins c-myc,
pubmed-meshheading:15517875-Pyrimidines
|
|
pubmed:articleTitle |
Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
|
|
pubmed:affiliation |
Department of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
